Research Analysts’ Recent Ratings Updates for Metlife (MET)

A number of firms have modified their ratings and price targets on shares of Metlife (NYSE: MET) recently:

  • 2/2/2018 – Metlife was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.
  • 1/31/2018 – Metlife had its “buy” rating reaffirmed by analysts at Goldman Sachs Group Inc.
  • 1/30/2018 – Metlife had its price target lowered by analysts at Wells Fargo & Co from $61.00 to $60.00. They now have a “buy” rating on the stock.
  • 1/22/2018 – Metlife was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “MetLife's efforts to streamline its business (for the past many years) to focus on the ones with potential for growth and fixing or exiting businesses that do not create value is impressive. Its strong international operations and disciplined capital management should drive long-term growth. Though the company has lost value in a year time, it remains an attractive investment opportunity, given its Value Score of A and undervaluation relative to the industry it belongs to. However, persistent decline in MetLife’s revenues, due to lower premiums, investment income, and fees collected from Universal Life and investment type product, and other revenues for more than two years bothers us.”
  • 1/18/2018 – Metlife was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $58.00 price target on the stock. According to Zacks, “MetLife's efforts to streamline its business (for the past many years) to focus on the ones with potential for growth and fixing or exiting businesses that do not create value is impressive. Its strong international operations and disciplined capital management should drive long-term growth. Though the company has lost value in a year time, it remains an attractive investment opportunity, given its Value Score of A and undervaluation relative to the industry it belongs to. However, persistent decline in MetLife’s revenues, due to lower premiums, investment income, and fees collected from Universal Life and investment type product, and other revenues for more than two years bothers us.”
  • 1/2/2018 – Metlife was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Shares of MetLife have underperformed the industry in the last year. Persistent decline in MetLife’s revenues, due to lower premiums, investment income, and fees collected from Universal Life and investment type product, and other revenues for more than two years bothers us. We are, however,  impressed with the company’s efforts to streamline its business (for the past many years) to focus on the ones with potential for growth and on fixing or exiting businesses that do not create value. Its strong international operations and disciplined capital management should drive long-term growth.”
  • 1/2/2018 – Metlife is now covered by analysts at Deutsche Bank AG. They set a “hold” rating and a $55.00 price target on the stock.
  • 12/18/2017 – Metlife was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Shares of MetLife have outperformed the industry in the last six months. We are impressed with the company’s efforts to streamline its business (for the past many years) to focus on the ones with potential for growth and on fixing or exiting businesses that do not create value. Its strong international operations and disciplined capital management should drive long-term growth. The stock has seen the Zacks Consensus Estimate for current-year earnings being revised 2.3% upward over the last 60 days. Nevertheless, persistent decline in MetLife’s revenues, due to lower premiums, investment income, and fees collected from Universal Life and investment type product, and other revenues for more than two years bothers us.”
  • 12/14/2017 – Metlife was given a new $62.00 price target on by analysts at Wells Fargo & Co. They now have a “buy” rating on the stock.

Shares of Metlife Inc (MET) opened at $44.61 on Monday. Metlife Inc has a 12-month low of $43.38 and a 12-month high of $55.91. The company has a debt-to-equity ratio of 0.31, a current ratio of 0.16 and a quick ratio of 0.16. The stock has a market cap of $46,943.06, a P/E ratio of -89.22, a price-to-earnings-growth ratio of 1.00 and a beta of 1.31.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Monday, February 5th will be given a $0.40 dividend. The ex-dividend date is Friday, February 2nd. This represents a $1.60 dividend on an annualized basis and a yield of 3.59%. Metlife’s payout ratio is -320.00%.

MetLife, Inc is a provider of life insurance, annuities, employee benefits and asset management. The Company’s segments include U.S.; Asia; Latin America; Europe, the Middle East and Africa (EMEA); MetLife Holdings, and Corporate & Other. Its U.S. segment is organized into Group Benefits, Retirement and Income Solutions and Property & Casualty businesses.

Receive News & Ratings for Metlife Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metlife Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply